OverviewSuggest Edit

Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.

Fusion provides contract services include...

- Antibody Humanization services

- Antibody Engineering Services

- Antibody sequencing Services

- Protein Expression & Purification Services

- Monoclonal Antibody services BLAST & Standard

- cGMP Services

Fusion Therapeutics (a division of Fusion Antibodies) is committed to developing therapeutic antibodies and recombinant proteins to disease specific markers. Fusion Therapeutics is primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record. The company’s genomic mining and proteomic discovery strategy has resulted in the development of a growing pipeline of candidate drugs. Fusion Antibodies have a number of exciting targets undergoing validation with two targets currently in preclinical trials.

TypePrivate
Founded2001
HQBelfast, GB
Websitefusionantibodies.com

Recent NewsAll News

Latest Updates

Employees (est.) (Oct 2019)31(+4%)
Revenue (FY, 2018)£2.7 M(+41%)

Key People/Management at Fusion Antibodies

Simon Douglas

Simon Douglas

Chairman of the Board
Paul Kerr

Paul Kerr

CEO
Richard Buick

Richard Buick

CTO
James Fair

James Fair

CFO
Sonya Ferguson

Sonya Ferguson

Non-Executive Director
Colin Walsh

Colin Walsh

Non-Executive Director
Show more

Fusion Antibodies Office Locations

Fusion Antibodies has an office in Belfast
Belfast, GB (HQ)
1 Springbank Road Springbank Industrial Est
Show all (1)

Fusion Antibodies Financials and Metrics

Summary Metrics

Founding Date

2001

Fusion Antibodies total Funding

$2.5 m

Fusion Antibodies latest funding size

$2.50 m

Time since last funding

12 years ago

Fusion Antibodies investors

Fusion Antibodies's latest funding round in July 2007 was reported to be $2.5 m. In total, Fusion Antibodies has raised $2.5 m
Show all financial metrics

Fusion Antibodies Revenue

Embed Graph
View revenue for all periods
Fusion Antibodies's revenue was reported to be £2.69 m in FY, 2018
GBP

Revenue (FY, 2018)

2.7m

Gross profit (FY, 2018)

1.5m

Gross profit margin (FY, 2018), %

55.1%

Net income (FY, 2018)

(699.9k)

EBITDA (FY, 2018)

(640.9k)

EBIT (FY, 2018)

(710.5k)

Cash (31-Mar-2018)

4.5m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2016FY, 2017FY, 2018

Revenue

609.3k455.9k461.1k436.9k492.3k435.2k405.0k723.0k1.5m1.9m2.7m

Revenue growth, %

79%

Cost of goods sold

802.9k255.2k248.6k196.3k298.7k361.7k324.2k365.3k618.1k952.5k1.2m

Gross profit

(193.6k)200.7k212.4k240.6k193.6k73.5k80.8k357.7k863.2k961.5k1.5m
GBPFY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

8.8k19.4k20.8k369.5k62.1k165.3k436.8k127.9k318.5k126.2k45.1k129.0k139.1k103.6k413.9k285.7k4.5m

Accounts Receivable

198.0k151.5k189.4k99.4k263.5k89.6k92.1k86.5k205.3k241.7k510.0k510.9k

Inventories

10.9k32.7k39.0k43.6k70.3k81.8k

Current Assets

23.2k110.7k198.9k645.4k384.0k645.3k783.7k508.5k565.5k563.8k287.6k248.3k269.2k309.0k691.6k930.0k5.5m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2016FY, 2017FY, 2018

Net Income

(815.8k)(1.1m)(1.3m)(960.2k)(533.9k)(752.2k)(468.7k)(113.5k)1.2m120.0k(699.9k)

Cash From Operating Activities

346.6k(37.4k)77.2k

Cash From Financing Activities

(496.0)(615.0)4.6m

Net Change in Cash

310.3k(128.3k)4.2m
GBPY, 2018

Revenue/Employee

152.3k

Financial Leverage

1.1 x
Show all financial metrics

Fusion Antibodies Online and Social Media Presence

Embed Graph

Fusion Antibodies Blogs

New technology for Affinity Maturation

Fusion Antibodies are working with a number of clients on pilot projects for their latest technology – RAMP™ – Rational Affinity Maturation Platform. RAMP™ was launched at the end of 2018 and clients have been coming on board to benefit from the innovative in silico approach to Affinity Maturation, …

De-risking antibody development

Why investing in pre-clinical activity is crucial to maximise the chance of success in clinical trials. The post De-risking antibody development appeared first on Fusion Antibodies.

Fusion Antibodies are CIR approved

Fusion Antibodies has been granted approval to participate in the Crédit Impôt Recherche (CIR) scheme, meaning our French clients can enjoy a significant tax break by partnering with us for pre-clinical antibody research. The post Fusion Antibodies are CIR approved appeared first on Fusion Antibodie…

Fusion Antibodies Frequently Asked Questions

  • When was Fusion Antibodies founded?

    Fusion Antibodies was founded in 2001.

  • Who are Fusion Antibodies key executives?

    Fusion Antibodies's key executives are Simon Douglas, Paul Kerr and Richard Buick.

  • How many employees does Fusion Antibodies have?

    Fusion Antibodies has 31 employees.

  • What is Fusion Antibodies revenue?

    Latest Fusion Antibodies annual revenue is £2.7 m.

  • What is Fusion Antibodies revenue per employee?

    Latest Fusion Antibodies revenue per employee is £86.8 k.

  • Who are Fusion Antibodies competitors?

    Competitors of Fusion Antibodies include Cmed, Tissue Regenix Group and Orthofix.

  • Where is Fusion Antibodies headquarters?

    Fusion Antibodies headquarters is located at 1 Springbank Road Springbank Industrial Est, Belfast.

  • Where are Fusion Antibodies offices?

    Fusion Antibodies has an office in Belfast.

  • How many offices does Fusion Antibodies have?

    Fusion Antibodies has 1 office.